KoBioLabs, Inc. Logo

KoBioLabs, Inc.

Develops AI-driven microbiome therapeutics for immune, metabolic, and brain disorders.

348150 | KO

Overview

Corporate Details

ISIN(s):
KR7348150004
LEI:
Country:
South Korea
Address:
서울특별시 관악구 관악로 1 220동 745-1호(신림동, 서울대학교종합연구동), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

KoBioLabs, Inc. is a biotechnology company specializing in the development of innovative microbiome therapeutics. The company utilizes its proprietary Smartiome® platform, an AI-driven, multi-omics drug discovery engine using a reverse-translation approach, to identify novel candidates for its pipelines. Its research and development efforts are primarily focused on creating treatments for a range of immune, metabolic, and brain disorders. KoBioLabs employs advanced technologies such as microbe-based drug delivery systems (mDDS) and biofoundry techniques to create a new class of drugs, aiming to address unmet medical needs by modulating biological pathways through microbial interactions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.2 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.3 KB
2025-03-31 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 14.1 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 483.3 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 225.0 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 17.6 KB
2025-02-14 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-14 00:00
Annual Report
[기재정정]사업보고서 (2023.12)
Korean 1.8 MB
2024-11-14 00:00
Quarterly Report
[기재정정]분기보고서 (2024.03)
Korean 1.1 MB
2024-11-14 00:00
Interim Report
[기재정정]반기보고서 (2024.06)
Korean 1.5 MB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.2 MB

Automate Your Workflow. Get a real-time feed of all KoBioLabs, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KoBioLabs, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KoBioLabs, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Atomera Inc Logo
Licenses semiconductor material and IP to enhance transistor performance and power efficiency.
United States of America
ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan
6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia
AEE
Avalo Therapeutics, Inc. Logo
Clinical-stage biotech developing IL-1β therapies for immune inflammatory diseases.
United States of America
AVTX
AVIS BUDGET GROUP, INC. Logo
Global provider of car rental, truck rental, and car-sharing for business & leisure travelers.
United States of America
CAR
Azenta, Inc. Logo
Life science solutions for pharma & biotech, offering sample management, storage & multiomics.
United States of America
AZTA
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan
6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom
BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway
BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden
BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.